This single-blind randomized controlled clinical trial investigated the effects of a 24-week Nordic walking (NW) training program on cognitive function in patients with mild/moderate Alzheimer's disease (AD). While the primary outcome (24-week change in MMSE scores) showed no significant difference between the NW group and the control group, secondary outcomes revealed significant improvements in the NW group for executive functions (FAB), selective attention and processing speed (SWCT), visual-spatial reasoning (CPM), and verbal episodic memory (RAVLT delayed recall). These findings suggest NW may offer a safe and effective strategy to decelerate cognitive decline in mild/moderate AD, warranting further research with larger samples and longer durations.
Publisher
Heliyon
Published On
Apr 28, 2023
Authors
A Angiolillo, D Leccese, S Ciccotelli, G Di Cesare, K D'elia, N Aurisano, C Matrone, C Dentizzi, A Di Costanzo
Tags
Nordic walking
Alzheimer's disease
cognitive function
executive functions
memory
randomized controlled trial
cognitive decline
Related Publications
Explore these studies to deepen your understanding of the subject.
